Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases.
$2.80+9.38%
报价 2026-11-09
市值
$120.3M
EV
$132.7M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -11.5%
$1.17$3.17
筛选结果
pipeline · 2026-11-09Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| LUNGPulmonx Corporation | $120.3M | +9.4% | +1.5% | 77.4% | – | – | – | |
| RLMDRelmada Therapeutics, Inc. | $441.6M | +6.2% | +300.0% | 0% | – | – | – | |
| IMUXImmunic, Inc. | $108.6M | +2.7% | -96.9% | 0% | – | – | – | |
| ACRVAcrivon Therapeutics, Inc. Common Stock | $67.7M | -1.9% | +1400.0% | 0% | – | – | – | |
| PMVPPMV Pharmaceuticals, Inc. | $66.7M | -0.8% | – | 0% | – | – | – | |
| HYPRHyperfine, Inc. | $64.3M | -1.8% | +50.7% | 51.4% | – | – | – | |
| TELATELA Bio, Inc. | $39M | +5.4% | +7.8% | 67.8% | – | – | – | |
| TCRXTScan Therapeutics, Inc. | $11.5M | -3.4% | -32.1% | 90.3% | – | – | – | |
| 同行中位数 | – | – | +29.3% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。